An immune alarm stuck in the on positionTLR7 gain-of-function variants · A sensor inside immune cells that normally detects viral genetic material is turned up too high, so it reacts to the body's own RNA as though it were an infection.
→Proven — in a small groupGlobal search
Search the evidence ledger
Find audited claims, source records, and selected trials. Search results preserve evidence type and route back to the full context.
The alarm gets delivered to the wrong placeUNC93B1 gain-of-function variants · A shuttle protein that escorts the RNA sensor to its correct compartment malfunctions, leaving the sensor active where it should be quiet.
→Proven — in a small groupThe body cannot clear its own cellular debrisDNASE1L3 loss of function, and acquired antibodies against it · An enzyme that chops up DNA released by dying cells is missing or blocked, so debris accumulates and the immune system starts treating it as a threat.
→Proven — in a small groupThe cleanup crew is understaffedComplement C1q/C4 deficiency and C4A copy number · Complement proteins tag dying cells for quiet disposal. Carrying fewer working copies leaves more debris around for the immune system to find.
→Proven — in a small groupImmune cells that attack the body survive when they should be deletedAutoreactive B-cell and plasma-cell lineage · B cells that recognise the body's own tissue normally get removed during development. In lupus they survive, multiply, and produce the antibodies that cause damage.
→Strong suspectAntibody factories that hide where drugs cannot reachLong-lived plasma cells (LLPCs) · Some antibody-producing cells settle into bone marrow and tissue niches, lose the marker most treatments target, and keep producing autoantibodies for years.
→Strong suspectAn antiviral alarm that never switches offType I interferon signalling · The body runs a permanent low-grade antiviral response with no virus present, which recruits more immune cells and worsens tissue damage.
→Strong suspectA common virus that rewires the wrong cellsEpstein–Barr virus (EBV) · Almost everyone carries EBV for life. In lupus it appears to settle preferentially in exactly the self-reactive B cells that cause trouble, and change how they behave.
→Strong suspectDying immune cells spill inflammatory materialNeutrophil extracellular traps and oxidised mitochondrial DNA · Certain white blood cells fling out webs of DNA when they die. The oxidised mitochondrial DNA in those webs is unusually good at triggering the antiviral alarm.
→Possible contributorGut bacteria that get somewhere they should not bePathobiont translocation and gut dysbiosis · Particular gut species cross the intestinal wall and reach liver and lymph tissue, where they appear to provoke autoimmunity; another species blooms during kidney flares.
→Possible contributorTwo X chromosomes mean a double dose of the alarm geneTLR7 escape from X-chromosome inactivation · The gene for the RNA sensor sits on the X chromosome, and in some immune cells it stays active on both copies — a plausible reason lupus affects women roughly nine times as often.
→Possible contributorThe immune system's brakes are wornRegulatory T-cell insufficiency · Regulatory T cells normally restrain immune responses. In lupus there appear to be too few working ones, so responses that should be damped keep running.
→Possible contributorImmune cells running their engines too hotmTOR activation and T-cell metabolic dysfunction · T cells in lupus show an altered metabolism that keeps them in an activated state, and drugs that dial that metabolism down appear to help.
→Possible contributorLow vitamin DVitamin D insufficiency · People with lupus often have low vitamin D, which led to a widespread belief that the deficiency helps cause the disease. Genetic evidence does not support that.
→Losing supportEstrogen and the contraceptive pill trigger flaresExogenous estrogen as a flare driver · Because lupus overwhelmingly affects women, estrogen was long assumed to drive flares — and people were routinely advised against combined contraceptives. Randomized trials did not bear this out.
→Ruled outRebuilding the immune system from scratchCD19-directed CAR T-cell therapy · A person's own T cells are re-engineered to hunt down and destroy every B cell in the body — including in tissue, not just blood — after which the immune system regrows from naive cells.
→Remission without ongoing drugs — seenA stronger antibody against B cellsObinutuzumab · An antibody infusion that depletes B cells more deeply than the older generation of the same drug class, given on top of standard treatment.
→Controls it, does not cure itSwitching off the false antiviral alarmAnifrolumab (type I interferon receptor blockade) · A monthly antibody that blocks the receptor for interferon, quieting the chronic antiviral response that drives inflammation.
→Controls it, does not cure itCutting off the survival signal for B cellsBelimumab and telitacicept (BAFF/APRIL blockade) · B cells depend on survival factors to persist. These drugs soak up those factors, so self-reactive B cells are less likely to survive.
→Controls it, does not cure itGoing after the hidden antibody factories tooCD19 plus BCMA-directed cell therapy · Adds a second target so the engineered cells also reach long-lived antibody-producing cells, which survive B-cell-only treatment.
→Being tested nowOff-the-shelf drugs against the antibody factoriesBCMA T-cell engagers and daratumumab · Rather than engineering cells for each patient, these are ready-made drugs — borrowed from myeloma treatment — that attack plasma cells directly.
→Being tested nowMaking the treatment inside the bodyIn vivo lipid-nanoparticle mRNA CAR-T · Instead of removing cells, engineering them in a facility, and infusing them back, an injection instructs the body to make the engineered cells itself.
→Being tested nowTurning the overactive alarm back downTLR7/8 inhibitors · Small molecules that block the sensor implicated by the rare genetic causes — the first lupus drug class to come directly out of genetics.
→Being tested nowReplacing the missing cleanup enzymeEngineered DNase biologics · Supplies a working version of the enzyme that clears DNA debris, for people who either lack it or make antibodies that block it.
→Being tested nowRestoring the immune system's brakesLow-dose interleukin-2 · Small doses of an immune signalling protein that selectively expand regulatory T cells — the cells that damp down immune responses.
→Being tested nowCooling down overactive immune cell metabolismSirolimus and related metabolic agents · Repurposed transplant and metabolic drugs that lower the metabolic activity keeping T cells switched on.
→Being tested nowProtecting the rebuild after a resetPost-CAR-T BAFF/APRIL blockade at B-cell return · When B cells start coming back after cell therapy, survival-factor levels surge — which may be exactly the window where self-reactive cells get rescued. Blocking those factors during the rebuild might make remission permanent.
→Nobody has tried it yetThe first attempt at removing B cellsRituximab · The original B-cell-depleting antibody. It works in other autoimmune diseases, and it is still used off-label in lupus — but it failed its randomized trials.
→Tried and failedPreventing lupus before it startsHydroxychloroquine in incomplete lupus · People with some lupus features but not enough for a diagnosis were given the standard lupus drug early, to see whether it would stop them progressing. It did not.
→Tried and failedTeaching the immune system to stand downTolerogenic peptides · Small protein fragments designed to retrain the immune system to stop attacking a specific self target — the most intuitive idea for a cure, and a consistent twenty-year failure.
→Tried and failedHydroxychloroquine is foundational therapy for most people with SLE when not contraindicatedCurrent major guidelines recommend hydroxychloroquine broadly in lupus, while dose, contraindications, interactions, and eye monitoring require individualized clinical care.
→established careCurrent treatment strategies seek to minimize long-term glucocorticoid exposureSteroids can be essential for rapid control, but current guidelines emphasize reducing ongoing exposure because cumulative treatment can cause substantial harm.
→established careLupus treatment depends on organ involvement, severity, reproductive context, comorbidities, and patient prioritiesThere is no single ranked treatment list for everyone with lupus. Kidney disease, pregnancy plans, infections, prior responses, access, and individual goals can change the safest option.
→established careThe FDA label includes obinutuzumab for adults with active lupus nephritis receiving standard therapyIn the United States, obinutuzumab has a lupus-nephritis indication for adults receiving standard therapy. Approval does not mean it is appropriate for every person or approved the same way everywhere.
→established careSmall early cohorts report remission after CD19 CAR-TIn small groups of people with very severe lupus that had not responded to multiple treatments, many entered remission after CD19 CAR-T. This is encouraging, but it is not yet a fair comparison with standard treatment.
→emerging preliminaryB-cell return after CAR-T may differ from the pretreatment stateIn early studies, B cells returned after a period of depletion and were mostly immature or naive cells. Researchers call this an immune-reset hypothesis; it has not been shown to permanently restore tolerance.
→human mechanistic evidenceEarly safety experience is limited and cannot exclude uncommon serious harmsThe first published lupus cohorts mostly reported low-grade cytokine release syndrome, but CAR-T also involves chemotherapy, a period of low B cells, and infection risk. Small studies cannot reveal rare harms.
→emerging preliminaryCAR-T has not been shown to outperform rituximab in SLECAR-T and rituximab should not be ranked from the available studies. The CAR-T reports involve selected patients and do not directly compare the treatments.
→contradictedProspective trials are testing CAR-T in SLE, but registry entries are not resultsSeveral formal studies are now following people with severe lupus who receive different CD19 CAR-T products. A trial listing tells us what researchers plan to measure; it does not show that the treatment works.
→emerging preliminaryEBV markers are associated with SLE, but the association is marker-specificPeople with lupus are more likely than controls to have some signs of previous or active EBV exposure. Because EBV is already very common and most studies look backward in time, this does not prove that the virus caused an individual's lupus.
→observational associationA 2025 human study identified an EBV-positive antigen-presenting B-cell program in SLEResearchers found a small population of EBV-infected B cells in lupus with gene activity that could help present self-antigens and activate other immune cells. It is a plausible mechanism, not yet a complete causal chain.
→human mechanistic evidenceCurrent evidence does not establish EBV as a necessary or sufficient cause of SLEEBV may contribute to lupus in some people, but it is not accurate to say that the virus explains all—or most—cases from the evidence available here.
→contradictedPreventing EBV has not been shown to prevent lupusAn EBV vaccine is an important research idea, but no lupus prevention trial has shown that vaccination lowers lupus risk.
→site hypothesisCAR-T remission cannot currently be attributed to elimination of EBV-positive B cellsCAR-T removes many CD19-positive B cells, which can include cells carrying EBV. The studies do not show that removing EBV-infected cells is why lupus improved.
→site hypothesisSLE is associated with altered gut microbial diversity and compositionAcross several studies, people with lupus had differences in gut microbial diversity and some bacterial groups compared with healthy controls. Medicines and active disease can also change the microbiome, so the direction of cause is unclear.
→observational associationRuminococcus gnavus expansion and strain-specific immunity correlate with active lupus nephritisOne human study found more R. gnavus in lupus and stronger antibody responses to particular strains in people with active kidney disease. This is a lead to investigate, not proof that the bacterium caused nephritis.
→observational associationA small uncontrolled FMT pilot reported SRI-4 responsesIn a 20-person pilot, 42.12% met a trial response measure after oral donor-microbiota capsules plus their usual stable treatment. Without a control group, we cannot know how much of that change came from FMT.
→emerging preliminaryMicrobiota transfer can modify lupus-like immune features in miceMoving gut microbes from lupus-prone mice into germ-free mice increased some lupus-related immune signals. That supports biological plausibility but does not tell us whether a microbiome treatment helps people.
→preclinical evidenceCurrent evidence does not show that a specific microbiome is required to initiate SLEThe microbiome may influence disease activity, but the evidence does not support calling it the single cause or an essential driver in every person with lupus.
→contradictedMicrobiome treatment after CAR-T is an untested combinationNo cited study shows that FMT, probiotics, or a selected bacterial mix makes CAR-T safer or more durable in lupus.
→site hypothesisAn interferon-inducible blood gene-expression pattern is present in a substantial SLE subgroupMany—but not all—people with active lupus have a high blood-gene pattern associated with type I interferon activity. This is a pathway signal, not a complete explanation of lupus or a stand-alone diagnostic test.
→human mechanistic evidenceType I interferon receptor blockade produced discordant primary-endpoint results across two phase 3 SLE trialsOne major anifrolumab trial met its main composite response endpoint; a closely related trial did not meet its different main endpoint. Together they support the pathway as clinically relevant while warning against describing the evidence as uniformly positive.
→supported clinical evidenceBaseline interferon-signature status is not a validated binary treatment-selection ruleA high interferon signature may describe biology, but current trial data do not justify using a simple high-versus-low result to guarantee or rule out response to interferon blockade.
→emerging preliminaryThe U.S. anifrolumab indication and safety warnings have explicit boundariesAnifrolumab is FDA-labeled for adults with moderate-to-severe SLE receiving standard therapy, but its label does not recommend it for severe active kidney or central-nervous-system lupus and highlights infection risks.
→established careCirculating BAFF/BLyS dysregulation is common but heterogeneous in SLEBAFF helps B cells survive, and abnormal BAFF measures occur in many people with lupus. Levels vary between people and over time, so a blood BAFF result is not a stand-alone measure of an individual's disease activity.
→observational associationBAFF inhibition improved a composite response outcome in active seropositive SLEIn BLISS-52, adding belimumab to standard therapy increased the proportion meeting the SRI composite at one year. The result is an average trial effect, not proof that every person's disease is BAFF-driven.
→supported clinical evidenceBelimumab added to standard therapy improved protocol-defined renal responses in active lupus nephritisIn a two-year kidney trial, more participants receiving belimumab plus standard therapy met the study's kidney-response definitions than participants receiving standard therapy alone. A response definition is not the same as kidney cure.
→supported clinical evidenceBAFF inhibition is not equivalent to eliminating all B cellsBelimumab blocks soluble BAFF/BLyS, a B-cell survival signal. That differs biologically and clinically from antibody-based B-cell depletion or CAR-T, even though all can affect the B-cell system.
→human mechanistic evidenceAnti-CD19 CAR T cell therapy for refractory systemic lupus erythematosusMackensen et al., Nature Medicine (2022) · case series
→SourceCD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-upMüller et al., New England Journal of Medicine (2024) · case series
→SourceKYSA-1: KYV-101 in subjects with refractory lupus nephritisClinicalTrials.gov NCT05938725 · trial registry
→SourceStudy of YTB323 in severe, refractory systemic lupus erythematosusClinicalTrials.gov NCT05798117 · trial registry
→SourceBreakfree-SLE: CC-97540 (BMS-986353; zola-cel) in active SLEClinicalTrials.gov NCT07015983 · trial registry
→SourceEpstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosusYounis et al., Science Translational Medicine (2025) · human mechanistic
→SourceSystematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosusHanlon et al., Arthritis Research & Therapy (2014) · systematic review
→SourceAssociation between systemic lupus erythematosus and disruption of gut microbiota: a meta-analysisXiang et al., Lupus Science & Medicine (2022) · systematic review
→SourceLupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensalAzzouz et al., Annals of the Rheumatic Diseases (2019) · case control
→SourceSafety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trialHuang et al., Journal of Autoimmunity (2022) · nonrandomized interventional
→SourceGut microbiota promote the inflammatory response in the pathogenesis of systemic lupus erythematosusMa et al., Molecular Medicine (2019) · animal model
→Source2021 DORIS definition of remission in SLE: final recommendations from an international task forcevan Vollenhoven et al., Lupus Science & Medicine (2021) · consensus definition
→SourceDefinition and initial validation of a Lupus Low Disease Activity State (LLDAS)Franklyn et al., Annals of the Rheumatic Diseases (2016) · consensus definition
→SourceNovel evidence-based systemic lupus erythematosus responder indexFurie et al., Arthritis & Rheumatism (2009) · consensus definition
→SourceFrom BILAG to BILAG-based combined lupus assessment—30 years onMurphy et al., Rheumatology (2016) · consensus definition
→Source2025 American College of Rheumatology Guideline for the Treatment of Systemic Lupus ErythematosusAmerican College of Rheumatology SLE guideline (2025) · guideline or regulatory
→SourceEULAR recommendations for the management of systemic lupus erythematosus: 2023 updateFanouriakis et al., Annals of the Rheumatic Diseases (2024) · guideline or regulatory
→SourceKDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKDIGO, Kidney International (2024) · guideline or regulatory
→SourceGAZYVA (obinutuzumab) prescribing informationU.S. FDA prescribing information (revised 2025) · guideline or regulatory
→SourceSystemic Lupus Erythematosus: Diagnosis, Treatment, and Steps to TakeNIH National Institute of Arthritis and Musculoskeletal and Skin Diseases · guideline or regulatory
→SourceInterferon-inducible gene expression signature in peripheral blood cells of patients with severe lupusBaechler et al., PNAS (2003) · human mechanistic
→SourceType I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialFurie et al., Lancet Rheumatology (2019) · randomized controlled trial
→SourceTrial of Anifrolumab in Active Systemic Lupus ErythematosusMorand et al., New England Journal of Medicine (2020) · randomized controlled trial
→SourceSAPHNELO (anifrolumab-fnia) prescribing informationU.S. FDA prescribing information (revised April 2026) · guideline or regulatory
→SourceB lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsStohl et al., Arthritis & Rheumatism (2003) · prospective cohort
→SourceAssociation of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusPetri et al., Arthritis & Rheumatism (2008) · prospective cohort
→SourceEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialNavarra et al., The Lancet (2011) · randomized controlled trial
→SourceTwo-Year, Randomized, Controlled Trial of Belimumab in Lupus NephritisFurie et al., New England Journal of Medicine (2020) · randomized controlled trial
→SourceBENLYSTA (belimumab) prescribing informationU.S. FDA prescribing information (revised June 2025) · guideline or regulatory
→SourceDevelopment of autoantibodies before the clinical onset of systemic lupus erythematosusArbuckle et al., New England Journal of Medicine (2003) · case control
→SourceTLR7 gain-of-function genetic variation causes human lupusBrown et al., Nature (2022) · human mechanistic
→SourceGain-of-function human UNC93B1 variants cause systemic lupus erythematosus and chilblain lupusDavid et al., Journal of Experimental Medicine (2024) · human mechanistic
→SourceLoss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosusAl-Mayouf et al., Nature Genetics (2011) · human mechanistic
→SourceAutoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosusHartl et al., Journal of Experimental Medicine (2021) · human mechanistic
→SourceComplement genes contribute sex-biased vulnerability in diverse disordersKamitaki et al., Nature (2020) · case control
→SourceAltered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classificationMunroe et al., Annals of the Rheumatic Diseases (2016) · case control
→SourceEpstein-Barr virus-associated infectious mononucleosis and risk of systemic lupus erythematosusUlff-Møller et al., Rheumatology (2010) · retrospective cohort
→SourceTranslocation of a gut pathobiont drives autoimmunity in mice and humansManfredo Vieira et al., Science (2018) · animal model
→SourceNeutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like diseaseLood et al., Nature Medicine (2016) · animal model
→SourceTLR7 escapes X chromosome inactivation in immune cellsSouyris et al., Science Immunology (2018) · human mechanistic
→SourceVitamin D level and risk of systemic lupus erythematosus and rheumatoid arthritis: a Mendelian randomizationBae & Lee, Clinical Rheumatology (2018) · case control
→SourceVitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trialHahn et al., BMJ (2022) · randomized controlled trial
→SourceA Randomized, Placebo-Controlled Trial of Hydroxychloroquine in Incomplete LupusOlsen et al., Arthritis & Rheumatology (2026) · randomized controlled trial
→SourceEfficacy and Safety of Obinutuzumab in Active Lupus NephritisFurie et al., New England Journal of Medicine (2025) · randomized controlled trial
→SourceEfficacy and Safety of Obinutuzumab in Active Systemic Lupus ErythematosusALLEGORY trial, New England Journal of Medicine (2026) · randomized controlled trial
→SourceA Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosusvan Vollenhoven et al., New England Journal of Medicine (2025) · randomized controlled trial
→SourceEfficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 StudyManzi et al., Arthritis & Rheumatology (2026) · randomized controlled trial
→SourceCD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trialMüller et al., Nature Medicine (2026) · nonrandomized interventional
→SourceCD19-CAR T-cell therapy induces deep tissue depletion of B cellsTur et al., Annals of the Rheumatic Diseases (2025) · human mechanistic
→SourceCo-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trialFeng et al., Nature Medicine (2025) · nonrandomized interventional
→SourceBCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cellsMüller et al., Nature Medicine (2025) · case report
→SourceCAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic reviewLi et al., Frontiers in Immunology (2026) · systematic review
→SourceTeclistamab-Induced Remission in Refractory Systemic Lupus ErythematosusAlexander et al., New England Journal of Medicine (2024) · case report
→SourceIn Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus ErythematosusNew England Journal of Medicine correspondence (2025) · case series
→SourceTargeted Degradation of NETs in Lupus with DNASE1L3 DeficiencyNew England Journal of Medicine correspondence (2026) · case report
→SourceLIBERATE-I: a phase 1b basket study of an engineered DNase in autoimmune diseaseClinicalTrials.gov registry record NCT07237659 · trial registry
→SourceDaratumumab in systemic lupus erythematosus: a single-arm phase 2 trialOstendorf et al., Nature Communications (2026) · nonrandomized interventional
→SourceLow dose IL-2 therapy restores regulatory T cells in patients with systemic lupus erythematosus in a dose-dependent manner: a phase IIb trialNature Communications (2026) · randomized controlled trial
→SourceSelective CAR T cell-mediated B cell depletion suppresses IFN signature in SLEWilhelm et al., JCI Insight (2024) · human mechanistic
→SourceSingle-cell profiling of the first characterised SLE relapse after CD19 CAR-T therapyAnoshkin et al., medRxiv preprint (2026) — not peer reviewed · preprint
→SourceEfficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosusMerrill et al., Arthritis & Rheumatism (2010) — EXPLORER · randomized controlled trial
→SourceB-cell depletion in the treatment of lupus nephritisGregersen & Jayne, Nature Reviews Nephrology (2012) · systematic review
→SourceAbetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trialCardiel et al., Arthritis & Rheumatism (2008) · randomized controlled trial
→SourceSafety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosusUrowitz et al., Lupus Science & Medicine (2015) · randomized controlled trial
→SourceCombined oral contraceptives in women with systemic lupus erythematosusPetri et al., New England Journal of Medicine (2005) — SELENA · randomized controlled trial
→SourceKYSA-1 · NCT05938725Adults with refractory class III or IV lupus nephritis
→active not recruitingYTB323 in severe refractory SLE · NCT05798117People with severe, refractory SLE
→active not recruitingBreakfree-SLE · NCT07015983People with active SLE, including lupus nephritis, despite glucocorticoids and at least two immunosuppressants
→recruiting